TABLE 4.
Treatment | DU (%) | IV (g I2/100 g) | SV | CN |
---|---|---|---|---|
Control | 87.71 ± 4.75 | 175.04 ± 9.93 | 194.3 ± 0.2 | 35 ± 2.2 |
N deficiency | 65.93 ± 2.42 | 118.11 ± 6.26 | 195.24 ± 0.37 | 47.67 ± 1.39 |
P deficiency | 51.59 ± 4.8 | 97.32 ± 6.59 | 196.11 ± 0.32 | 56.29 ± 2.53 |
1% Y42 supernatant | 82.66 ± 4.67 | 163.12 ± 7.15 | 194.97 ± 1.57 | 38.22 ± 2.19 |
3% Y42 supernatant | 35.3 ± 6.42 | 47.53 ± 3.83 | 198.61 ± 3.29 | 63.47 ± 3.01 |
5% Y42 supernatant | 36.22 ± 7.47 | 31.69 ± 4.52 | 205.19 ± 4.31 | 66.38 ± 3.86 |
DU, degree of unsaturation {(monounsaturated fatty acids [wt%]) + 2(polyunsaturated fatty acids [wt%])}; IV, iodine value; SV, saponification value; CN, cetane number.